Industry News


Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.


Please click here to submit your news.

ZeptoMetrixto Release NATtrol Inactivated Zika Virus for the Development of Molecular Diagnostic Assays and Ongoing Clinical Laboratory Quality Control

ZeptoMetrix™ Corporation (ZMC), announced today the release of several new products to aid in the rapid development and ongoing quality control of molecular assays targeting the Zika Virus.

"Our level of concern with the Zika Virus outbreak is extremely high," Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed to his Executive Team. "We need to support the molecular diagnostic industry with accurate, reliable and non-infectious tools to alleviate the level of uncertainty that exists. These molecular based assays are without a doubt the most sensitive and specific ways to identify and monitor a Zika Virus infection."

To complement its current Tropical Disease microorganism offerings, ZeptoMetrix has added 3 strains of Zika Virus for the development and verification of molecular diagnostic assays. These strains can be used to optimize test sensitivity. Other arboviruses from the ZeptoMetrix collection, such as Dengue Virus, Yellow Fever, and Chikungunya can be used to test that an assay is specific for the Zika Virus.

For clinical laboratory use, ZeptoMetrix has treated Zika Virus with its proprietary NATtrol™ inactivation process to manufacture non-infectious, molecular testing controls and an assay range validation panel. Together, these quality controls products can be utilized to verify test performance, track variations in results, follow lot-to-lot test kit reproducibility, monitor individual operator performance and determine aberrant long-term trends in laboratory results.

Post a Comment

Previous Post Next Post

Contact Form